Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6849448

Title:Pigs and pig cells having an inactivated α 1,3-galactosyl transferase gene
Inventors:D'Apice, Anthony J. F.; Balwyn, Australia
Summary:This invention describes a new alpha-1,3-galactosyltransferase and leukaemia inhibitor factor, its corresponding DNA and nucleic acid constructs for inactivating the transferase gene. The invention relates to human pre-formed xenoantibodies which play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed herein are materials and methods for removing or neutralizing such antibodies, as well as materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are described as forming as the result of activity by the enzyme alpha-1,3 galactosyltransferase. Also included is the porcine gene encoding alpha-1,3 galactosyltransferase and methods of inactivating the gene in mammalian cells and embryos. Nucleic acid constructs are provided which are useful for inactivating the alpha-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture. Also discussed are therapeutic applications such as in the elimination of hyperacute regions in human transplants.
Abstract:Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme α-1,3 galactosyltransferase. The porcine gene encoding α-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the α-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the α-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6849448
Application Number:US1997000984900
Date Filed:04/12/1997
Date Published:01/02/2005
Assignee:BresaGen Limited Australia


 
Copyright © 2007 The Institute for Cellular Medicine  8/13/2020